ASCO's living guideline for recurrent epithelial ovarian cancer recommends platinum doublets if platinum-sensitive and strongly recommends mirvetuximab soravtansine if platinum-resistant with FRα expression; evidence for secondary cytoreduction or HIPEC is insufficient.
Guidelinen = 147 publications
Lesnock et al. Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0